Abstract
Although PI3-kinase mutations are uncommon in renal cell carcinoma (RCC), the PI3-kinase/Akt signaling pathway is active in most RCC. The activation of PI3-kinase would be expected to drive protein and lipid synthesis through its effects on mTORC1 and SREBP1, respectively. PI3-kinase also activates numerous transcription factors (e.g. the FOXO family, c-myc, NF-κB) that regulate cell proliferation and viability. The consequences of blocking PI3-kinase in RCC are just now beginning to be elucidated and are expected to include effects on tumor cell proliferation, metabolism, and angiogenesis. Several PI3-kinase inhibitors currently undergoing clinical testing are active site inhibitors of mTOR as well and it is likely that these agents will prove particularly useful in the treatment of RCC.
Keywords: Everolimus, mTOR, renal cell carcinoma, PI3-kinase, temsirolimus, translation.
Current Cancer Drug Targets
Title:Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Volume: 13 Issue: 2
Author(s): Daniel C. Cho and James W. Mier
Affiliation:
Keywords: Everolimus, mTOR, renal cell carcinoma, PI3-kinase, temsirolimus, translation.
Abstract: Although PI3-kinase mutations are uncommon in renal cell carcinoma (RCC), the PI3-kinase/Akt signaling pathway is active in most RCC. The activation of PI3-kinase would be expected to drive protein and lipid synthesis through its effects on mTORC1 and SREBP1, respectively. PI3-kinase also activates numerous transcription factors (e.g. the FOXO family, c-myc, NF-κB) that regulate cell proliferation and viability. The consequences of blocking PI3-kinase in RCC are just now beginning to be elucidated and are expected to include effects on tumor cell proliferation, metabolism, and angiogenesis. Several PI3-kinase inhibitors currently undergoing clinical testing are active site inhibitors of mTOR as well and it is likely that these agents will prove particularly useful in the treatment of RCC.
Export Options
About this article
Cite this article as:
C. Cho Daniel and W. Mier James, Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma, Current Cancer Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1568009611313020003
DOI https://dx.doi.org/10.2174/1568009611313020003 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Protein Multiple Conformations: A Structure-Based Strategy for Kinase Drug Design
Current Topics in Medicinal Chemistry Intraperitoneal Drug Therapy: An Advantage
Current Clinical Pharmacology Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Role of Nanomedicine in Hepatic Targeting- Deciphering Strategies with Molecular Insights and Preclinical Prospects
Drug Delivery Letters A Review on The Role of VEGF in Tamoxifen Resistance
Anti-Cancer Agents in Medicinal Chemistry Modifying Radiation Damage
Current Drug Targets Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism CYP2A5 Induction and Hepatocellular Stress: An Adaptive Response to Perturbations of Heme Homeostasis
Current Drug Metabolism Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Current Pharmaceutical Design Targeting the mTOR Pathway in Tumor Malignancy
Current Cancer Drug Targets PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides
Current Radiopharmaceuticals The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs
Current Pharmacogenomics